Heart Failure With Preserved Ejection Fraction

Cardiovascular·MeSH: Heart Failure

Prevalence

1800.0 / 100K

Incidence

300.0 / 100K/yr

11 drugs in development·7 companies·11 clinical trials

Drug Pipeline by Phase

Phase 2(8)

Drug	Company
Activin ligand-trap biological therapy	Valneva SE (VALN)
Antiretroviral Therapy	Valneva SE (VALN)
cdr132l	Cardiol Therapeutics Inc. (CRDL)
ck-4021586 (150 mg	CYTOKINETICS INC (CYTK)
EDG-15400	Edgewise Therapeutics, Inc. (EWTX)
pl-3994 aqueous intravenous solution dose ascention	PALATIN TECHNOLOGIES INC (PTN)
pl-3994 aqueous intravenous solution single dose	PALATIN TECHNOLOGIES INC (PTN)
tx45	Tectonic Therapeutic, Inc. (TECX)

Phase 1(2)

Drug	Company
cdr132l	Cardiol Therapeutics Inc. (CRDL)
CK-586	CYTOKINETICS INC (CYTK)

Phase 1/Phase 2(1)

Drug	Company
tn-301	Tenaya Therapeutics, Inc. (TNYA)

BioSniper tracks 11 drugs in development for Heart Failure With Preserved Ejection Fraction across 7 companies.

There are 11 clinical trials targeting Heart Failure With Preserved Ejection Fraction tracked by BioSniper.

The estimated prevalence of Heart Failure With Preserved Ejection Fraction is approximately 1800.0 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.